Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Kenneth S. Thress
ResearcherPublications, citations & collaboration network
Kenneth S. Thress is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 108 works, 7,973 citations, an h-index of 28 and an i10-index of 36.
108
Works
7,973
Citations
28
h-index
36
i10-index
IDs:OpenAlex
How has Kenneth S. Thress's publication output changed over time?
ScholarIQpublication output · 1996–2020
Output grew0% over the shown period — from 1 works in 1996 to 1 in 2020.
1
3
2
3
1
1
199620152016201720182020
What are the most-cited papers on Kenneth S. Thress?
ScholarIQmost cited works
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard
Nature Medicine. 20151,558 CitationsOPEN ACCESS
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden, Rachael Lawrance, Cloud P. Paweletz, Mireille Cantarini, James Chih‐Hsin Yang, J. Carl Barrett, Pasi A. Jänne
Journal of Clinical Oncology. 2016846 CitationsOPEN ACCESS
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard, James Yates, Zhenfan Yang, Dong‐Wan Kim, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, Mike Hickey, Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne, Darren A.E. Cross
Clinical Cancer Research. 2016725 Citations
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, Hatim Husain, Daniel B. Costa, Philip Tracy, Nora Feeney, Lynette M. Sholl, Suzanne E. Dahlberg, Amanda J. Redig, David J. Kwiatkowski, Michael S. Rabin, Cloud P. Paweletz, Kenneth S. Thress, Pasi A. Jänne
JAMA Oncology. 2018691 CitationsOPEN ACCESS
Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee, Takayasu Kurata, Dong‐Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, Pasi A. Jänne
Journal of Clinical Oncology. 2017544 Citations
Related on ScholarIQ
AstraZeneca (South Korea)
Institution
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Paper
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Paper
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Paper
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Paper
Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Paper